» Articles » PMID: 37601008

Modeling Parkinson's Disease in LRRK2 Rodents

Overview
Journal Neuronal Signal
Date 2023 Aug 21
PMID 37601008
Authors
Affiliations
Soon will be listed here.
Abstract

Mutations in the leucine-rich repeat kinase 2 () gene are associated with familial and sporadic forms of Parkinson's disease (PD). Sporadic PD and LRRK2 PD share main clinical and neuropathological features, namely hypokinesia, degeneration of nigro-striatal dopamine neurons and α-synuclein aggregates in the form of Lewy bodies. Animals harboring the most common LRRK2 mutations, i.e. p.G2019S and p.R1441C/G, have been generated to replicate the parkinsonian phenotype and investigate the underlying pathogenic mechanisms. Disappointingly, however, LRRK2 rodents did not consistently phenocopy hypokinesia and nigro-striatal degeneration, or showed Lewy body-like aggregates. Instead, LRRK2 rodents manifested non-motor signs and dysregulated transmission at dopaminergic and non-dopaminergic synapses that are reminiscent of behavioral and functional network changes observed in the prodromal phase of the disease. LRRK2 rodents also manifested greater susceptibility to different parkinsonian toxins or stressors when subjected to dual-hit or multiple-hit protocols, confirming LRRK2 mutations as genetic risk factors. In conclusion, LRRK2 rodents represent a unique tool to identify the molecular mechanisms through which LRRK2 modulates the course and clinical presentations of PD and to study the interplay between genetic, intrinsic and environmental protective/risk factors in PD pathogenesis.

Citing Articles

LRRK2 in Drosophila Melanogaster Model: Insights into Cellular Dysfunction and Neuroinflammation in Parkinson's Disease.

Ciampelli C, Galleri G, Galioto M, Mereu P, Pirastru M, Bernardoni R Int J Mol Sci. 2025; 26(5).

PMID: 40076730 PMC: 11900240. DOI: 10.3390/ijms26052093.


The AAV-α-Synuclein Model of Parkinson's Disease: An Update.

Bjorklund A, Mattsson B J Parkinsons Dis. 2024; 14(6):1077-1094.

PMID: 39031386 PMC: 11380285. DOI: 10.3233/JPD-240207.

References
1.
Longo F, Russo I, Shimshek D, Greggio E, Morari M . Genetic and pharmacological evidence that G2019S LRRK2 confers a hyperkinetic phenotype, resistant to motor decline associated with aging. Neurobiol Dis. 2014; 71:62-73. PMC: 4194318. DOI: 10.1016/j.nbd.2014.07.013. View

2.
Belloli S, Morari M, Murtaj V, Valtorta S, Moresco R, Gilardi M . Translation Imaging in Parkinson's Disease: Focus on Neuroinflammation. Front Aging Neurosci. 2020; 12:152. PMC: 7289967. DOI: 10.3389/fnagi.2020.00152. View

3.
Dranka B, Gifford A, Ghosh A, Zielonka J, Joseph J, Kanthasamy A . Diapocynin prevents early Parkinson's disease symptoms in the leucine-rich repeat kinase 2 (LRRK2R¹⁴⁴¹G) transgenic mouse. Neurosci Lett. 2013; 549:57-62. PMC: 3729885. DOI: 10.1016/j.neulet.2013.05.034. View

4.
Postuma R, Lang A, Gagnon J, Pelletier A, Montplaisir J . How does parkinsonism start? Prodromal parkinsonism motor changes in idiopathic REM sleep behaviour disorder. Brain. 2012; 135(Pt 6):1860-70. DOI: 10.1093/brain/aws093. View

5.
Ramonet D, Daher J, Lin B, Stafa K, Kim J, Banerjee R . Dopaminergic neuronal loss, reduced neurite complexity and autophagic abnormalities in transgenic mice expressing G2019S mutant LRRK2. PLoS One. 2011; 6(4):e18568. PMC: 3071839. DOI: 10.1371/journal.pone.0018568. View